Puma Biotechnology Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Hi, everyone. Thanks for joining us today. I'm proud to introduce CEO from Puma Biotechnology, Alan Auerbach.
Great. Thank you. Just a reminder, I'll be making forward-looking statements.
So on this slide, you can see our product pipeline with our drug neratinib. Neratinib is currently approved in the United States and in Europe for the extended adjuvant treatment of HER2-positive breast cancer. We also have ongoing studies in the metastatic setting that includes the third-line NALA trial that we filed the sNDA on in June of this year and then 2 other trials, the FB-10 and the NEfERTT trial.
We also are specifically looking at neratinib in patients with brain mets, and that's the TBCRC 022 trial. And then we have an area that we've most recently expanded, which is the HER2 mutations and specifically in breast cancer, and that's with our SUMMIT study where we're looking at neratinib in breast cancer and cervical cancer as well as other
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
